ProtAb Overview

  • Founded
  • 2005
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

ProtAb General Information


Developer of pharmaceutical therapies intended for the treatment of autoimmune diseases. The company's therapies creates a humanized monoclonal antibody, targeting a 16-amino acid surface epitope of the mycobacterial Heat Shock Protein 65 and its mammalian homolog, HSP60, enabling doctors with therapies to treat autoimmune diseases.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Jerusalem Bio Park
  • Jerusalem
  • Israel
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ProtAb Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Dec-2017 000 Completed Out of Business
3. Early Stage VC (Series A) 23-Apr-2010 000 000 Completed Generating Revenue
2. Grant $2M $3M Completed Generating Revenue
1. Seed Round $3M $3M Completed Generating Revenue
To view ProtAb’s complete valuation and funding history, request access »